These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21651497)

  • 21. Therapeutic protein kinase inhibitors.
    Grant SK
    Cell Mol Life Sci; 2009 Apr; 66(7):1163-77. PubMed ID: 19011754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PI3K inhibitors for cancer treatment: where do we stand?
    Maira SM; Stauffer F; Schnell C; García-Echeverría C
    Biochem Soc Trans; 2009 Feb; 37(Pt 1):265-72. PubMed ID: 19143644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protein kinase inhibitors: breakthrough medicines and the next generation.
    Sawyer TK; Wu JC; Sawyer JR; English JM
    Expert Opin Investig Drugs; 2013 Jun; 22(6):675-8. PubMed ID: 23705633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer drug development. Preface.
    Sawyers CL; Mellinghoff IK
    Curr Top Microbiol Immunol; 2012; 355():v-vi. PubMed ID: 23227490
    [No Abstract]   [Full Text] [Related]  

  • 25. Focus issue: choreographing the dance of the mitotic kinases.
    Gough NR
    Sci Signal; 2011 Jun; 4(179):eg5. PubMed ID: 21712543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review).
    Ardito F; Giuliani M; Perrone D; Troiano G; Lo Muzio L
    Int J Mol Med; 2017 Aug; 40(2):271-280. PubMed ID: 28656226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of regulators and inhibitors of Pim-1, a serine/threonine kinase, for tumour therapy (review).
    Liang C; Li YY
    Mol Med Rep; 2014 Jun; 9(6):2051-60. PubMed ID: 24737044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pharmacogenomics of drug resistance to protein kinase inhibitors.
    Gillis NK; McLeod HL
    Drug Resist Updat; 2016 Sep; 28():28-42. PubMed ID: 27620953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug resistance, epigenetics, and tumor cell heterogeneity.
    Hoey T
    Sci Transl Med; 2010 Apr; 2(28):28ps19. PubMed ID: 20410528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted cancer therapy.
    Sawyers C
    Nature; 2004 Nov; 432(7015):294-7. PubMed ID: 15549090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative network mapping of the human kinome interactome reveals new clues for rational kinase inhibitor discovery and individualized cancer therapy.
    Cheng F; Jia P; Wang Q; Zhao Z
    Oncotarget; 2014 Jun; 5(11):3697-710. PubMed ID: 25003367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting cell cycle kinases for cancer therapy.
    de Cárcer G; Pérez de Castro I; Malumbres M
    Curr Med Chem; 2007; 14(9):969-85. PubMed ID: 17439397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the Kinome II.
    Hemmings BA; Restuccia D; Tonks N
    Curr Opin Cell Biol; 2009 Apr; 21(2):135-9. PubMed ID: 19342212
    [No Abstract]   [Full Text] [Related]  

  • 34. Going for broke: targeting the human cancer pseudokinome.
    Bailey FP; Byrne DP; McSkimming D; Kannan N; Eyers PA
    Biochem J; 2015 Jan; 465(2):195-211. PubMed ID: 25559089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug efficacy testing in mice.
    Kim WY; Sharpless NE
    Curr Top Microbiol Immunol; 2012; 355():19-38. PubMed ID: 21823029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug discovery: inhibitors that activate.
    Cichowski K; Jänne PA
    Nature; 2010 Mar; 464(7287):358-9. PubMed ID: 20237552
    [No Abstract]   [Full Text] [Related]  

  • 37. Leveraging Structural Diversity and Allosteric Regulatory Mechanisms of Protein Kinases in the Discovery of Small Molecule Inhibitors.
    Verkhivker GM
    Curr Med Chem; 2017; 24(42):4838-4872. PubMed ID: 27719654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinase profiling in early stage drug discovery: sorting things out.
    Defert O; Boland S
    Drug Discov Today Technol; 2015 Nov; 18():52-61. PubMed ID: 26723893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. mTOR pathway inhibitors in cancer therapy: moving past rapamycin.
    Wacheck V
    Pharmacogenomics; 2010 Sep; 11(9):1189-91. PubMed ID: 20860456
    [No Abstract]   [Full Text] [Related]  

  • 40. Tyrosine kinases as targets for cancer therapy.
    Krause DS; Van Etten RA
    N Engl J Med; 2005 Jul; 353(2):172-87. PubMed ID: 16014887
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.